Cyclo-oxygenase 2 inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 3-4 Business Days
DelveInsight’s, “Cyclo-oxygenase 2 inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Cyclo-oxygenase 2 inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Cyclo-oxygenase 2 inhibitors: Overview
COX-2 inhibitors are a type of nonsteroidal anti-inflammatory drug (NSAID) that directly targets cyclooxygenase-2, COX-2, an enzyme responsible for inflammation and pain. Targeting selectivity for COX-2 reduces the risk of peptic ulceration and is the main feature of celecoxib, rofecoxib, and other members of this drug class. COX-2 appears to be related to cancers and abnormal growths in the intestinal tract. COX inhibitors have been shown to reduce the occurrence of cancers and pre-cancerous growths. COX-2 inhibitors have been found to be effective in suppressing inflammatory neurodegenerative pathways in mental illness, with beneficial results in trials for major depressive disorder as well as schizophrenia. The inhibition of COX-2 is paramount for the anti-inflammatory and analgesic function of the selective COX-2 inhibitor celecoxib.
Report Highlights
This segment of the Cyclo-oxygenase 2 inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cyclo-oxygenase 2 inhibitors Emerging Drugs
Further product details are provided in the report……..
Cyclo-oxygenase 2 inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Cyclo-oxygenase 2 inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Cyclo-oxygenase 2 inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Cyclo-oxygenase 2 inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cyclo-oxygenase 2 inhibitors drugs.
Cyclo-oxygenase 2 inhibitors Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Cyclo-oxygenase 2 inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Cyclo-oxygenase 2 inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Cyclo-oxygenase 2 inhibitors: Overview
COX-2 inhibitors are a type of nonsteroidal anti-inflammatory drug (NSAID) that directly targets cyclooxygenase-2, COX-2, an enzyme responsible for inflammation and pain. Targeting selectivity for COX-2 reduces the risk of peptic ulceration and is the main feature of celecoxib, rofecoxib, and other members of this drug class. COX-2 appears to be related to cancers and abnormal growths in the intestinal tract. COX inhibitors have been shown to reduce the occurrence of cancers and pre-cancerous growths. COX-2 inhibitors have been found to be effective in suppressing inflammatory neurodegenerative pathways in mental illness, with beneficial results in trials for major depressive disorder as well as schizophrenia. The inhibition of COX-2 is paramount for the anti-inflammatory and analgesic function of the selective COX-2 inhibitor celecoxib.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Cyclo-oxygenase 2 inhibitors R&D. The therapies under development are focused on novel approaches for Cyclo-oxygenase 2 inhibitors.
This segment of the Cyclo-oxygenase 2 inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cyclo-oxygenase 2 inhibitors Emerging Drugs
- Bardoxolone methyl: Reata Pharmaceuticals
- ALLOD-2: Allodynic Therapeutics
Further product details are provided in the report……..
Cyclo-oxygenase 2 inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Cyclo-oxygenase 2 inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Cyclo-oxygenase 2 inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Cyclo-oxygenase 2 inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Cyclo-oxygenase 2 inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cyclo-oxygenase 2 inhibitors drugs.
Cyclo-oxygenase 2 inhibitors Report Insights
- Cyclo-oxygenase 2 inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Cyclo-oxygenase 2 inhibitors drugs?
- How many Cyclo-oxygenase 2 inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cyclo-oxygenase 2 inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cyclo-oxygenase 2 inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Cyclo-oxygenase 2 inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Reata Pharmaceuticals
- Allodynic Therapeutics
- Promius Pharma
- Merck & Co.
- AFT Pharmaceuticals
- Kadmon Corporation
- Arthritis Innovation Corporation
- Simcere
- Immix Biopharma
- Sirnaomics
- Layerbio
- Jiangsu HengRui Medicine
- Orexo
- Neumentum
- Orbis Biosciences
- ARKAY Therapeutics
- Virios Therapeutics
- Addpharma
- Tavanta Therapeutics
- Astellas Pharma
- Teikoku Seiyaku
- YooYoung Pharmaceuticals
- Tremeau Pharmaceuticals
- MedWell Laboratories
- RaQualia Pharma
- Bardoxolone
- ALLOD 2
- DFD-07
- MK 0663
- AXS 07
- Acetaminophen/ibuprofen
- YIV 906
- mdc-CWM
- OX338
- Iguratimod
- Valacyclovir/celecoxib
- RQ-00317076
- TRM 201
- MW 001
- YYC301
- DRGT 46
- SC-58635
- Esflurbiprofen transdermal
- AD 2111
- Imx-110
- STP 705
- RK-01
- ORB-210
- NTM 004
- OcuRing-K™
- Imrecoxib
Introduction
Executive Summary
Cyclo-oxygenase 2 inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Cyclo-oxygenase 2 inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Preregistration)
Comparative Analysis
Bardoxolone methyl: Reata Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
DRGT 46: Tavanta Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
OX338: Orexo
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
NTM 004: Neumentum
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Cyclo-oxygenase 2 inhibitors Key Companies
Cyclo-oxygenase 2 inhibitors Key Products
Cyclo-oxygenase 2 inhibitors- Unmet Needs
Cyclo-oxygenase 2 inhibitors- Market Drivers and Barriers
Cyclo-oxygenase 2 inhibitors- Future Perspectives and Conclusion
Cyclo-oxygenase 2 inhibitors Analyst Views
Cyclo-oxygenase 2 inhibitors Key Companies
Appendix
Executive Summary
Cyclo-oxygenase 2 inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Cyclo-oxygenase 2 inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Preregistration)
Comparative Analysis
Bardoxolone methyl: Reata Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
DRGT 46: Tavanta Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
OX338: Orexo
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
NTM 004: Neumentum
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Cyclo-oxygenase 2 inhibitors Key Companies
Cyclo-oxygenase 2 inhibitors Key Products
Cyclo-oxygenase 2 inhibitors- Unmet Needs
Cyclo-oxygenase 2 inhibitors- Market Drivers and Barriers
Cyclo-oxygenase 2 inhibitors- Future Perspectives and Conclusion
Cyclo-oxygenase 2 inhibitors Analyst Views
Cyclo-oxygenase 2 inhibitors Key Companies
Appendix